Sierra Gross, MD
Internal Medicine · Sheridan, WYNPI 1649698366
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $219 and has fallen 74.3% since, to $56 in 2025.
Across 39 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$116
- GSK$109
- Pfizer$77
- Lilly USA, LLC$58
- Boston Scientific$56
- Sanofi-aventis U.S. LLC$43
- plus $207 from 9 others
What the payments were for
- Food & beverage$63195%
- Education$355%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $116 |
| GSK | 6 | $109 |
| Pfizer | 4 | $77 |
| Lilly USA, LLC | 4 | $58 |
| Boston Scientific | 1 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| AbbVie(2 entities) | 2 | $42 |
| AstraZeneca | 2 | $28 |
| Amgen | 2 | $27 |
| Abbott | 1 | $24 |
| Organon | 2 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Novartis | 1 | $14 |
How this compares
$666 in reported general payments places this provider in the 85th percentile of 101 internal medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 12 | $189 |
| Pantoprazole Sodium | 12 | $138 |
| Atorvastatin Calcium | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Sheridan
- David WalkerSheridan$3K
- Juli AckermanSheridan$3K
- Hannah HallSheridan$3K
- Kristopher SchamberSheridan$2K
- Derek RedingerSheridan$1K
- Erin HendersonSheridan$991
- Allison DawsonSheridan$684
- Elise SylarSheridan$270
- Abigail TurnboughSheridan$144
- Kim FehirSheridan$126
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.